MESENCHYMAL STROMAL CELLS MAY ENHANCE RESIDUAL HEALTHY HAEMATOPOIESIS IN LOW-RISK MDS PATIENTS

被引：0

作者：

Jimenez Solas, T. ^{[1
]}

Muntion Olave, S. ^{[1
]}

Lopez, F. ^{[1
]}

Ortega Herrera, R. ^{[1
]}

Martin Izquierdo, M. ^{[2
]}

Gonzalez Martinez, T. ^{[2
]}

Janusz, K. ^{[3
]}

Ezponda, T. ^{[4
]}

Vilas, A. ^{[4
]}

Alfonso, A. ^{[5
]}

Prosper, F. ^{[5
]}

Molero, A. ^{[6
]}

Valcarcel, D. ^{[7
]}

Sanchez-Guijo, F. ^{[1
]}

Diez-Campelo, M. ^{[1
]}

机构：

[1] Hosp Univ Salamanca, IBSAL, Hematol, Salamanca, Spain

[2] Canc Res Ctr Salamanca, Hematol, Salamanca, Spain

[3] Inst Maimonides Invest Biomed Cordoba, Biol Celular Hematol, Cordoba, Spain

[4] Univ Navarra, IDISNA, Ctr Invest Med Aplicada CIMA, Oncol Hematol, Pamplona, Spain

[5] Univ Navarra, IDISNA, Ctr Invest Med Aplicada CIMA, Hematol, Pamplona, Spain

[6] Univ Autonoma Barcelona UAB, Vall dHebron Hosp, Barcelona, Spain

[7] Vall dHebron Inst Oncol VHIO, Expt Hematol Unit, Barcelona, Spain

来源：

LEUKEMIA RESEARCH | 2021年 / 108卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P36

引用

页码：S39 / S39

页数：1

共 50 条

[1] MESENCHYMAL CELLS AS A POTENTIAL THERAPEUTIC TOOL IN THE IMPROVEMENT OF RESIDUAL HEALTHY HEMATOPOIESIS IN LOW-RISK SMD PATIENTS
Jimenez, Solas Tamara
Muntion, Olave Sandra
Lopez, Cadenas Felix
Ortega, Herrera Rebeca
Martin, Izquierdo Marta
Gonzalez, Martinez Teresa
Januz, Kamila
Ezponda, Itoiz Teresa
Vilas, Amaia
Alfonso, Ana
Prosper, Felipe
Molero, Antonieta
Valcarcel, David
Sanchez-Guijo, Martin Fermin
Diez, Campelo Maria
HAEMATOLOGICA, 2020, 105 : 235 - 236
[2] Mesenchymal stromal cells support significant engraftment of low-risk myelodysplastic syndromes (MDS) in a murine xenograft model
Medyouf, H.
Mossner, M.
Nolte, F.
Jann, J. C.
Nowak, V.
Zens, B.
Muedder, K.
Oblaender, J.
Fey, S.
Fabarius, A.
Riedl, E.
Marx, A.
Roehl, H.
Mueller, N.
Metzgeroth, G.
Huetter, G.
Hofmann, W. K.
Trumpp, A.
Nowak, D.
LEUKEMIA RESEARCH, 2013, 37 : S14 - S14
[3] Mesenchymal stromal cells from MDS with 5q-show different genetic and epigenetic changes compared to those from other low-risk MDS
Muntion, S.
Santamaria, C.
Diez-Campelo, M.
Chillon, C.
Gonzalez, M.
Lopez-Villar, O.
Blanco, B.
De las Rivas, J.
San Miguel, J. F.
Sanchez-Guijo, F. M.
Del Canizo, C.
LEUKEMIA RESEARCH, 2013, 37 : S128 - S129
[4] Clonal Evolution in Patients with Low-Risk MDS
Mazzeo, P.
Ganster, C.
Brzuszkiewicz, E. B.
Rittscher, K.
Kamper, M.
Goetze, K.
Mueller-Thomas, C.
Balaian, E.
Sockel, K.
Platzbecker, U.
Shirneshan, K.
Haase, D.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 36 - 36
[5] Impaired Expression of Focal Adhesion Kinase in Mesenchymal Stromal Cells from Low-Risk Myelodysplastic Syndrome Patients
Wu, Yuenv
Aanei, Carmen Mariana
Kesr, Sanae
Picot, Tiphanie
Guyotat, Denis
Catafal, Lydia Campos
FRONTIERS IN ONCOLOGY, 2017, 7 : 164
[6] Diagnosis of immune pathophysiology in patients with low-risk MDS
Nakao, S.
LEUKEMIA RESEARCH, 2009, 33 : S1 - S1
[7] TRANSFUSION BURDEN AMONG LOW-RISK MDS PATIENTS
Dubow, J.
Guerci, A.
Gyan, E.
Dupuis-Sireva, A.
LEUKEMIA RESEARCH, 2021, 108 : S27 - S27
[8] Lenalidomide treatment modulates proliferation and differentiation of human mesenchymal stromal cells from healthy donors and MDS patients
Wobus, M.
Duennebier, G.
Bornhaeuser, M.
Ehninger, G.
Platzbecker, U.
LEUKEMIA RESEARCH, 2009, 33 : S44 - S44
[9] Lenalidomide Modulates the Phenotype and Function of Human Mesenchymal Stromal Cells From Healthy Donors and MDS Patients.
Wobus, Manja
Duennebier, Gwendolin
Feldmann, Silvia
Ehninger, Gerhard
Bornhauser, Martin
Platzbecker, Uwe
BLOOD, 2009, 114 (22) : 1468 - 1468
[10] Defined xeno-free media enhance expansion of mesenchymal stromal cells from bone marrow of MDS patients
Altrock, E.
Sens-Albert, C.
Hofmann, F.
Riabov, V
Schmitt, N.
Xu, Q.
Jann, J-C
Rapp, F.
Steiner, L.
Streuer, A.
Nowak, V
Oblaender, J.
Weimer, N.
Palme, I
Gol, M.
Darwich, A.
Wuchter, P.
Metzgeroth, G.
Jawhar, M.
Wofmann, W-K
Nowak, D.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 135 - 135

← 1 2 3 4 5 →